Creo Medical Group (LON:CREO) Posts Earnings Results

Creo Medical Group (LON:CREO) issued its quarterly earnings data on Friday. The company reported GBX (0.04) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 600 million for the quarter. Creo Medical Group had a net margin of 768.18% and a return on equity of 32.72%.

Creo Medical Group Stock Up 27.5%

CREO opened at GBX 14.50 on Friday. The company has a debt-to-equity ratio of 6.90, a current ratio of 5.28 and a quick ratio of 2.19. The company’s 50-day moving average is GBX 12.09 and its 200 day moving average is GBX 12.18. Creo Medical Group has a fifty-two week low of GBX 9.52 and a fifty-two week high of GBX 18.50. The firm has a market capitalization of £59.81 million, a P/E ratio of -14.50 and a beta of 1.62.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Creo Medical Group in a report on Thursday, April 16th.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.